Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Company research

DEVONIAN HEALTH GROUP INC COM NEW (Canada)

CIK 2000684Updated Mar 3, 2026

DVHGF price & chart

Provider market data

Loading TradingView…

OTC:DVHGF on TradingView ↗

TradingView · Data may be delayed

About the company

We are a biopharmaceutical company focused on developing and commercializing immunomodulatory treatments for inflammatory diseases with high unmet medical needs. Our current portfolio is comprised of treatment candidates with significant potential to address immune-mediated inflammatory diseases. Although inflammation is at the root of several known chronic health conditions1,2,3, we focus on conditions in the areas of dermatology, gastroenterology, hepatology and fibrosis. We have developed a portfolio of patented cosmetic products and are looking for a partner for its commercialization, however, we will primarily be focusing on advancing our therapeutic research and development (“R&D”) pipeline.

F-1/A · 2026-09-02 · 0001104659-26-104757

Company description from the cited filing.

In the news

Seeking Alpha

Recent filings

  1. F-1/A filing

    F-1/A · 2026-09-02 · 0001104659-26-104757

  2. F-1 filing

    F-1 · 2026-07-27 · 0001104659-26-087148

Offerings

Registration 333-297734

F-1/A · 2026-09-02 · 0001104659-26-104757

Terms from the governing filing for this registration; not a claim that the offering is open today.